"Looks like Cerebos was at least partially right when they highlighted the riskiness of the earnings stream."
Trilogy International forecasts a small first-half loss while tipping a second-half pickup which would help it to almost meet guidance for the full year.
The Dunedin-based NZX-listed bioscience company says the recent success of a first-phase trial on dogs has encouraged an expanded trial.
"If they can nail their marketing (a decent website would be a start) then they sky is the limit."
Sign up for NBR subscriber content or email alerts
The easiest way for subscribers to stay logged in is to click the "Remember Me" option on the Member Log In box on the top right of this page.